Laura E G Warren1, Cynthia L Miller1, Nora Horick2, Melissa N Skolny1, Lauren S Jammallo1, Betro T Sadek1, Mina N Shenouda1, Jean A O'Toole3, Shannon M MacDonald1, Michelle C Specht4, Alphonse G Taghian5. 1. Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts. 2. Department of Biostatistics, Massachusetts General Hospital, Boston, Massachusetts. 3. Department of Physical and Occupational Therapy, Massachusetts General Hospital, Boston, Massachusetts. 4. Division of Surgical Oncology, Massachusetts General Hospital, Boston, Massachusetts. 5. Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts. Electronic address: ataghian@partners.org.
Abstract
PURPOSE/ OBJECTIVE: Lymphedema after breast cancer treatment can be an irreversible condition with a negative impact on quality of life. The goal of this study was to identify radiation therapy-related risk factors for lymphedema. METHODS AND MATERIALS: From 2005 to 2012, we prospectively performed arm volume measurements on 1476 breast cancer patients at our institution using a Perometer. Treating each breast individually, 1099 of 1501 patients (73%) received radiation therapy. Arm measurements were performed preoperatively and postoperatively. Lymphedema was defined as ≥10% arm volume increase occurring >3 months postoperatively. Univariate and multivariate Cox proportional hazard models were used to evaluate risk factors for lymphedema. RESULTS: At a median follow-up time of 25.4 months (range, 3.4-82.6 months), the 2-year cumulative incidence of lymphedema was 6.8%. Cumulative incidence by radiation therapy type was as follows: 3.0% no radiation therapy, 3.1% breast or chest wall alone, 21.9% supraclavicular (SC), and 21.1% SC and posterior axillary boost (PAB). On multivariate analysis, the hazard ratio for regional lymph node radiation (RLNR) (SC ± PAB) was 1.7 (P=.025) compared with breast/chest wall radiation alone. There was no difference in lymphedema risk between SC and SC + PAB (P=.96). Other independent risk factors included early postoperative swelling (P<.0001), higher body mass index (P<.0001), greater number of lymph nodes dissected (P=.018), and axillary lymph node dissection (P=.0001). CONCLUSIONS: In a large cohort of breast cancer patients prospectively screened for lymphedema, RLNR significantly increased the risk of lymphedema compared with breast/chest wall radiation alone. When considering use of RLNR, clinicians should weigh the potential benefit of RLNR for control of disease against the increased risk of lymphedema.
PURPOSE/ OBJECTIVE:Lymphedema after breast cancer treatment can be an irreversible condition with a negative impact on quality of life. The goal of this study was to identify radiation therapy-related risk factors for lymphedema. METHODS AND MATERIALS: From 2005 to 2012, we prospectively performed arm volume measurements on 1476 breast cancerpatients at our institution using a Perometer. Treating each breast individually, 1099 of 1501 patients (73%) received radiation therapy. Arm measurements were performed preoperatively and postoperatively. Lymphedema was defined as ≥10% arm volume increase occurring >3 months postoperatively. Univariate and multivariate Cox proportional hazard models were used to evaluate risk factors for lymphedema. RESULTS: At a median follow-up time of 25.4 months (range, 3.4-82.6 months), the 2-year cumulative incidence of lymphedema was 6.8%. Cumulative incidence by radiation therapy type was as follows: 3.0% no radiation therapy, 3.1% breast or chest wall alone, 21.9% supraclavicular (SC), and 21.1% SC and posterior axillary boost (PAB). On multivariate analysis, the hazard ratio for regional lymph node radiation (RLNR) (SC ± PAB) was 1.7 (P=.025) compared with breast/chest wall radiation alone. There was no difference in lymphedema risk between SC and SC + PAB (P=.96). Other independent risk factors included early postoperative swelling (P<.0001), higher body mass index (P<.0001), greater number of lymph nodes dissected (P=.018), and axillary lymph node dissection (P=.0001). CONCLUSIONS: In a large cohort of breast cancerpatients prospectively screened for lymphedema, RLNR significantly increased the risk of lymphedema compared with breast/chest wall radiation alone. When considering use of RLNR, clinicians should weigh the potential benefit of RLNR for control of disease against the increased risk of lymphedema.
Authors: Joseph Ragaz; Ivo A Olivotto; John J Spinelli; Norman Phillips; Stewart M Jackson; Kenneth S Wilson; Margaret A Knowling; Christopher M L Coppin; Lorna Weir; Karen Gelmon; Nhu Le; Ralph Durand; Andrew J Coldman; Mohamed Manji Journal: J Natl Cancer Inst Date: 2005-01-19 Impact factor: 13.506
Authors: Marek Ancukiewicz; Cynthia L Miller; Melissa N Skolny; Jean O'Toole; Laura E Warren; Lauren S Jammallo; Michelle C Specht; Alphonse G Taghian Journal: Breast Cancer Res Treat Date: 2012-06-19 Impact factor: 4.872
Authors: M Overgaard; P S Hansen; J Overgaard; C Rose; M Andersson; F Bach; M Kjaer; C C Gadeberg; H T Mouridsen; M B Jensen; K Zedeler Journal: N Engl J Med Date: 1997-10-02 Impact factor: 91.245
Authors: Anthony Lucci; Linda Mackie McCall; Peter D Beitsch; Patrick W Whitworth; Douglas S Reintgen; Peter W Blumencranz; A Marilyn Leitch; Sukumal Saha; Kelly K Hunt; Armando E Giuliano Journal: J Clin Oncol Date: 2007-05-07 Impact factor: 44.544
Authors: Nicole L Stout Gergich; Lucinda A Pfalzer; Charles McGarvey; Barbara Springer; Lynn H Gerber; Peter Soballe Journal: Cancer Date: 2008-06-15 Impact factor: 6.860
Authors: Lee Gravatt Wilke; Linda M McCall; Katherine E Posther; Pat W Whitworth; Douglas S Reintgen; A Marilyn Leitch; Sheryl G A Gabram; Anthony Lucci; Charles E Cox; Kelly K Hunt; James E Herndon; Armando E Giuliano Journal: Ann Surg Oncol Date: 2006-03-02 Impact factor: 5.344
Authors: Sarah A McLaughlin; Mary J Wright; Katherine T Morris; Gladys L Giron; Michelle R Sampson; Julia P Brockway; Karen E Hurley; Elyn R Riedel; Kimberly J Van Zee Journal: J Clin Oncol Date: 2008-10-06 Impact factor: 44.544
Authors: Gunel Guliyeva; Maria T Huayllani; Daniel Boczar; Francisco R Avila; Xiaona Lu; Antonio Jorge Forte Journal: J Cancer Surviv Date: 2021-01-24 Impact factor: 4.442
Authors: Susan G R McDuff; Amir I Mina; Cheryl L Brunelle; Laura Salama; Laura E G Warren; Mohamed Abouegylah; Meyha Swaroop; Melissa N Skolny; Maria Asdourian; Tessa Gillespie; Kayla Daniell; Hoda E Sayegh; George E Naoum; Hui Zheng; Alphonse G Taghian Journal: Int J Radiat Oncol Biol Phys Date: 2018-08-28 Impact factor: 7.038
Authors: Pragati G Advani; Xiudong Lei; Cameron W Swanick; Ying Xu; Yu Shen; Nathan A Goodwin; Grace L Smith; Sharon H Giordano; Kelly K Hunt; Reshma Jagsi; Benjamin D Smith Journal: Int J Radiat Oncol Biol Phys Date: 2019-02-01 Impact factor: 7.038
Authors: Cheryl L Brunelle; Meyha N Swaroop; Melissa N Skolny; Maria S Asdourian; Hoda E Sayegh; Alphonse G Taghian Journal: Phys Ther Date: 2018-06-01